On-Demand CME Videos
'5 in 5' Tips on Managing the 'Itch-Scratch Cycle' of Prurigo Nodularis with Biologics
About
This 10-minute microlearning discussion is designed to provide "5 practical tips" on Prurigo Nodularis management that you can incorporate into clinical practice. Learn through short bursts of information focused on clinical diagnosis, disease burden, the role of biologics, patient-centered management and treatment timing.
This activity is supported by educational grants from Galderma, and Sanofi and Regeneron Pharmaceuticals, Inc.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 8, 2024
March 10, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the impact of prurigo nodularis (PN) on patient quality of life, including sleep quality and mental health
Review efficacy and safety data for approved and emerging biologics to manage PN
Discuss patient-centered strategies for integrating new and emerging biologics for PN into clinical care
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Raj Chovatiya, MD, PhD, MSCI
Clinical Associate Professor, Rosalind Franklin University Chicago Medical School Founder and Director, Center for Medical Dermatology and Immunology Research
Chicago, IL
Sarina Elmariah, MD, PhD, MPH
Director, UCSF Itch and Neurosensory Center
Associate Professor of Dermatology
University of California San Francisco
San Francisco, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB
Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB
Advisory Board: Bellus Health, Galderma, Pfizer, Sanofi Regeneron, Trevi Therapeutics
Speaker's Bureau: Eli Lilly, Pfizer
Ownership Interest: Frontier Bio
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.